Charles River Laboratories stock (US1591881009): CLSA upgrade lifts the focus

Charles River Laboratories attracted new buy-side and sell-side attention on 05/29/2026 after CLSA analyst Michael Luo raised the stock from Hold to Outperform and increased the price target to USD 219.00 from USD 167.00, according to reporting relayed by GuruFocus and Fintel. The shares were last quoted at USD 181.34, placing the move in the context of the U.S.-listed stock on Nasdaq and the broader life-sciences tools group in the United States.

The upgrade is notable because it follows a clear target reset rather than a small technical adjustment, and it gives investors a fresh reference point for Charles River Laboratories on the eve of the new month. A separate MarketBeat item on 05/29/2026 also noted that Zacks Research trimmed earnings estimates for the company, with the current full-year EPS consensus cited at USD 11.05 and the next-quarter estimate lowered to USD 2.72 from USD 2.85.

As of: 05/30/2026

By the editorial team - specialized in equity coverage.

Charles River Laboratories: core business model

Charles River Laboratories provides preclinical and laboratory services that support drug development, with demand tied mainly to pharmaceutical and biotechnology research spending.

Recent corporate actions

No positive evidence of a completed delisting or take-private was identified in the available dated sources, so the stock continues to be treated as actively listed on Nasdaq. The latest catalyst in the dated record is still the 05/29/2026 analyst upgrade, which kept the market focused on valuation and earnings expectations rather than on capital-structure changes.

Latest quarterly results for Charles River Laboratories at a glance

The most recent verified quarterly figures were not provided in the dated sources available for this article, so the cleanest near-term readthrough comes from consensus revisions rather than a new earnings release. On 05/29/2026, MarketBeat cited Zacks Research as lowering the quarter estimate to USD 2.72 from USD 2.85 while keeping the full-year consensus at USD 11.05 per share.

That means the current debate is centered on how much earnings momentum can support the higher target set by CLSA on the same day. For U.S. investors, the key home-market frame remains the Nasdaq listing and the reaction of the domestic sell-side to the company's 2026 outlook.

Conclusion

The main short-term driver for Charles River Laboratories is the 05/29/2026 CLSA upgrade, which resets the discussion around both valuation and earnings potential in the U.S. market. The lower near-term earnings estimate cited the same day suggests investors will continue to watch whether the new USD 219.00 target is matched by fundamentals.

The article remains centered on the Nasdaq-listed U.S. name, with the latest dated evidence pointing to analyst action rather than to any corporate transaction. That keeps the next catalyst squarely on execution and the next round of research updates.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.